Now Playing
Opinion|Videos|September 19, 2024
Myelofibrosis: Background, Risk Stratification, and Treatment Decision-Making
Author(s)David M. Swoboda, MD, Andrew T. Kuykendall, MD
Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.
Advertisement
Episodes in this series
Advertisement
Related to this article
Israel approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS, expanding access beyond the US, UK, EU, Saudi Arabia, and UAE.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
A dual bispecific regimen of pasritamig and JNJ-9401 reduced PSA by at least 50% in 73% of heavily pretreated patients with metastatic CRPC.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Results showed a 33% confirmed ORR and a 7.4-month median PFS with serabelisib and sapanisertib plus paclitaxel in advanced endometrioid endometrial cancer.
Psychiatrists explain where ketamine and esketamine show real promise for depression in patients with cancer and where caution is still needed.
In a phase 2 study, azacitidine plus ruxolitinib produced a 78% objective response rate in patients with chronic phase myelofibrosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5